论文部分内容阅读
目的:研究黄芩苷抑制静脉桥术后内膜增生的作用及其机理。方法:通过建立动脉粥样硬化兔模型,在此基础上建立颈外静脉-颈总动脉移植模型,实验过程中用黄芩苷(中药组)进行干预,同期用西药非诺贝特(西药组)进行对照干预。测定血清肿瘤坏死因子(TNF-α)及白细胞介素6(IL-6)含量,并检测静脉桥内膜、中膜厚度。结果:中药中、高剂量预防组,中药中、高剂量治疗组与西药预防、治疗组比较,能有效降低TNF-α、IL-6的含量(P<0.05);中药预防各组,中药中、高剂量治疗组与西药预防、治疗组比较,静脉桥内膜增生厚度明显降低(P<0.05);且呈剂量依赖关系,黄芩苷给药浓度越高,上述作用越明显。结论:黄芩苷具有减缓静脉桥血管内皮细胞和平滑肌的细胞增殖,从而起到抑制静脉桥内膜增生的作用。
Objective: To study the effect of baicalin on intimal hyperplasia after venous bypass and its mechanism. Methods: A rabbit model of atherosclerosis was established. On this basis, a model of external jugular vein-common carotid artery transplantation was established. Baicalin (Chinese medicine group) was used to intervene in the experiment. Western medicine fenofibrate (western medicine group) Control interventions. Serum tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) levels were measured and the intima-media thickness and medial thickness of venous grafts were measured. Results: The levels of TNF-α and IL-6 in medium and high dose prophylaxis group and traditional Chinese medicine medium and high dose treatment group were significantly lower than those in western medicine prophylaxis and treatment group (P <0.05) Compared with western medicine prevention and treatment group, the thickness of intimal hyperplasia in the high-dose group was significantly decreased (P <0.05), and the dose-dependent relationship between the dosage of baicalin and the high dose group was more obvious. Conclusion: Baicalin can slow down the cell proliferation of vascular endothelial cells and smooth muscle of venous bridge and thus play a role in inhibiting the intimal hyperplasia of venous bridge.